PTGX Q3 2019 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-32.3% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$17M-414.6% margin

Net Income

-$16M-396.3% margin

EPS (Diluted)

$-0.61

QoQ Revenue Growth

+150.6%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$155M

Total Liabilities

$59M

Stockholders' Equity

$95M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$6M	-32.3%
Gross Profit	$4M	$6M	-32.3%
Operating Income	-$17M	-$9M	-82.8%
Net Income	-$16M	-$9M	-87.9%

Revenue Segments

License And Collaborative Revenue

$4M100%